Pressure to publish jumps. And researchers have no time to do science. (New survey from Elsevier) Survey of 3200 researchers: 1. Only 45% of scientists have sufficient time for actual research. 2. For 68%, the pressure to publish today is greater than 2-3 years ago. 3. 29% of

Original Article: Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis (PISCES trial) https://t.co/m4W5oUljyX Editorial: Fish Oil for Patients Receiving Hemodialysis — Red Herring or Great Catch? https://t.co/MRvzOdneNP @ASNKidney | #KidneyWk

Genetic causes of renal tubular Acidosis. #KidneyWk

📌ASIs (inhibidores de la síntesis de aldosterona) frente a MRAs: 1️⃣ Reducción eficaz de la PA. 2️⃣ Mucho menor incidencia de hiperkalemia (<1%). 3️⃣ Lorundrostat y Baxdrostat avanzan en fases 3 de ensayo✍🏻👇🏻 #KidneyWk

Monogenic cause for kidney stones #KidneyWk

🔥Must know recent FDA✅drugs nephro🆕 ✅Daprodustat-oral HIF-PHI anemia in CKD ✅Pegunigalsidase alpha-Fabry ✅Rivfloza-RNA interference- 1 hyperoxaluria ✅Sparsentan-IgA Neph ✅Letermovir-CMV Ds in kid Tx ✅Tenapanor-⬆️PO4 in CKD ✅Empagliflozin-⬇️CKD prog #KidneyWk

#Nephpearls Managing RAASi with Hyperkalemia 🔑🩸 K-based approach 👇 ✅ K < 5.0 →Continue RAASi ⚠️ K 5.0–5.5 → Continue but optimize 🚨 K 5.5–6.0 → Reduce dose ± start K-binders (SZC/Patiromer) ❗ K > 6.0 → Hold RAASi, Rx hyperkalemia, re-introduce with care #KidneyWk

🚨 Just released: ASN Kidney Health Guidance on Potassium & Phosphorus Food Additives. Learn to understand risk differences, manage hyperkalemia and CKD-MBD risk, identify foods with additives, and target interventions to improve care for people living with kidney diseases.

🧬APOL1: Updates of the H3Africa study by @ulasi_ifeomai at #KidneyWk 👏🏽

Phase 1b RCT results on Farabursen for ADPKD by @AlanYuNeph -Increased urinary PC1 and PC2 vs placebo -A reduction in ht-TKV was observed (≥2mg) -Safety profile was tolerable with favorable safety results Looking forward to seeing more results

💡New paradigm: aim to achieve #CKD remission

Chronic interstitial nephritis in agricultural communities #KidneyWk

A Drug Screening Platform for Podocytopathies in Drosophila Nephrocytes ca. 2025 from @asnpublications #Nephpearls #BestofJASN #KidneyWk #VisualAbstract by @deniise_am 👉 https://t.co/YQkcAQEFLQ

💊 En el estudio CONFIDENCE, iniciar finerenona + empagliflozina simultáneamente logró una reducción temprana y aditiva del UACR (-52%), superior a cada fármaco por separado (−32% vs empa, −29% vs fine). Sinergia cardiorrenal real. 🔬 #KidneyWk @SOMANEorg @SENefrologia

@ASNKidney 💬 Editorial: Estrella et al show that integrated cystatin C and creatinine measurements improve CKD assessment compared to single-marker estimates. #KidneyWk @ASNKidney https://t.co/3FLLfWS80M

💥💥Endotelina: de vasoconstrictor a protagonista cardio-renal. Implica mecanismos clave en ERC, proteinuria e inflamación renal. Equilibrio entre receptores ETₐ (daño) y ET_b (protección) @PepaSolerR #KidneyWk @SENefrologia @SOMANEorg

🧬🧬Some monogenic kidney disease with specific therapies 👍 🧬👇#KidneyWk ✅Fabry-Enzyme replacement ✅ATTR amyloid-Patisiran ✅APOL Nephropathy-Inaxaplin ✅Primary hyperoxaluria-Nidosiran ✅Liddle-Amiloride ✅Corticosteroid remediable aldosteronism-glucocorticoid

Is this on your #KidneyWk schedule? A leading bioinformatics researcher, Julio Saez-Rodriguez, will deliver a state-of-the-art lecture on “Systems Biology of Kidney Diseases” at a plenary session on Friday, November 7, followed by an expert panel. https://t.co/kkJYdBC75u

How to approach individuals at risk of genetic kidney diseases #KidneyWk

New review in #ASNJASN and simultaneously published with the #KidneyWk plenary session: “Responsible Use of Artificial Intelligence (AI) to Improve Kidney Care: A Statement from the American Society of Nephrology.” Check out the article here: https://t.co/atlOdJ3y0D